Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06271668 · ClinicalTrials.gov registry record
Clinical Decision Support to Improve System Naloxone Co-prescribing
A clinical trial, sponsored by University of Colorado, Denver.
- Active
- Registry status
- 200,000
- Enrollment target
NCT06271668: Active study, sponsored by University of Colorado, Denver.
NCT06271668 is a clinical trial that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 200,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06271668 is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- 200,000 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the impact of a clinical decision support (CDS) alert to facilitate the co-prescribing of naloxone, an opioid overdose reversal agent, with high-risk opioid prescriptions. Prescribing naloxone with opioids is a best practice described in the 2022 US Center for Disease Control and Prevention (CDC) guidelines on opioid prescribing. The CDS can improve quality of care delivered by improving compliance with the guideline defined best practices. The project will compare CDS alert facilitated co-prescribing of naloxone with high-risk opioid prescriptions vs usual care to evaluate the effectiveness of the CDS alert for improving naloxone prescribing. The patients are not assigned to an intervention and will be receiving any changes in care as part of their routine medical care, rather than a specific intervention that is distinct from their usual medical care. The researchers hypothesize that the CDS alert will be acceptable to providers while increasing naloxone co-prescribing which will reduce the number of opioid overdoses in subsequent 6 months.
Primary Outcome
The number of high-risk opioid encounters where a naloxone prescription was written with the opioid divided by the total number of encounters where a high-risk opioid prescription was written.
Interventions
- OTHER Naloxone Co-prescribing Clinical Decision Support (CDS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200,000 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2026-10 |
What the registry record for NCT06271668 still lists
NCT06271668 is an observational study that tracks outcomes without assigning an intervention. Its 200,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Naloxone Co-prescribing Clinical Decision Support (CDS) is the first listed.
NCT06271668 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06271668 about?
NCT06271668 is a clinical study titled "Clinical Decision Support to Improve System Naloxone Co-prescribing". The objective of this study is to evaluate the impact of a clinical decision support (CDS) alert to facilitate the co-prescribing of naloxone, an opioid overdose reversal agent, with high-risk opioid prescriptions. Prescribing naloxone with opioids is a best practice described in the 2022 US Center ...
What is the current status of trial NCT06271668?
This trial is currently active not recruiting. The enrollment target is 200,000 participants. The study started on 2024-07-01. Estimated completion is 2026-10.
What interventions are being tested in trial NCT06271668?
The interventions under investigation include: Naloxone Co-prescribing Clinical Decision Support (CDS) (OTHER).
Who is sponsoring clinical trial NCT06271668?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI